# ACTIV-6

> **NIH NIH U24** · DUKE UNIVERSITY · 2022 · $20,600,000

## Abstract

ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel betacoronavirus that first emerged
in December 2019 and has since caused a global pandemic unseen in almost a century with respect to the
number of cases and overall mortality. Over 2020, advances were made for treatment of COVID-19 and
several vaccinations have received emergency use authorization for prevention of SARS-CoV-2 infections.
However, the pandemic continues to evolve with new variants and surges of infections in different regions of
the world, requiring an ongoing evidence-generating platform, in particular for the oral treatment of COVID-19
infection in the outpatient setting. To address this unmet need the Duke Clinical Research Institute, Vanderbilt
University Medical Center and partners are coming together to coordinate ACTIV-6 as a platform with a master
clinical trial protocol that can serve as an evidence generating system for prioritized drugs repurposed from
other indications with an established safety record and preliminary evidence of clinical efficacy for the
treatment of COVID-19.

## Key facts

- **NIH application ID:** 10652817
- **Project number:** 3U24TR001608-07S1
- **Recipient organization:** DUKE UNIVERSITY
- **Principal Investigator:** DANIEL K. BENJAMIN
- **Activity code:** U24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $20,600,000
- **Award type:** 3
- **Project period:** 2022-09-26 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10652817

## Citation

> US National Institutes of Health, RePORTER application 10652817, ACTIV-6 (3U24TR001608-07S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10652817. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*